164 related articles for article (PubMed ID: 37399248)
1. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Calabresi L; Carretta C; Romagnoli S; Rotunno G; Parenti S; Bertesi M; Bartalucci N; Rontauroli S; Chiereghin C; Castellano S; Gentili G; Maccari C; Vanderwert F; Mannelli F; Della Porta M; Manfredini R; Vannucchi AM; Guglielmelli P
Am J Hematol; 2023 Oct; 98(10):1520-1531. PubMed ID: 37399248
[TBL] [Abstract][Full Text] [Related]
2. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
3. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
4. What are the molecular mechanisms driving the switch from MPNs to leukemia?
Wang X; Hoffman R
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
[TBL] [Abstract][Full Text] [Related]
5. Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.
Lasho TL; Mudireddy M; Finke CM; Hanson CA; Ketterling RP; Szuber N; Begna KH; Patnaik MM; Gangat N; Pardanani A; Tefferi A
Blood Adv; 2018 Feb; 2(4):370-380. PubMed ID: 29467191
[TBL] [Abstract][Full Text] [Related]
6. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
8. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
[TBL] [Abstract][Full Text] [Related]
9. Clonal dynamics in a case of acute monoblastic leukemia that later developed myeloproliferative neoplasm.
Sato S; Itonaga H; Taguchi M; Sawayama Y; Imanishi D; Tsushima H; Hata T; Moriuchi Y; Mishima H; Kinoshita A; Yoshiura KI; Miyazaki Y
Int J Hematol; 2018 Aug; 108(2):213-217. PubMed ID: 29417354
[TBL] [Abstract][Full Text] [Related]
10. Characterization of disease-propagating stem cells responsible for myeloproliferative neoplasm-blast phase.
Wang X; Rampal RK; Hu CS; Tripodi J; Farnoud N; Petersen B; Rossi MR; Patel M; McGovern E; Najfeld V; Iancu-Rubin C; Lu M; Davis A; Kremyanskaya M; Weinberg RS; Mascarenhas J; Hoffman R
JCI Insight; 2022 Apr; 7(8):. PubMed ID: 35259128
[TBL] [Abstract][Full Text] [Related]
11. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
Pegliasco J; Hirsch P; Marzac C; Isnard F; Meniane JC; Deswarte C; Pellet P; Lemaitre C; Leroy G; Rabadan Moraes G; Guermouche H; Schmaltz-Panneau B; Pasquier F; Colas C; Benusiglio PR; Bera O; Bourhis JH; Brissot E; Caron O; Chraibi S; Cony-Makhoul P; Delaunay-Darivon C; Lapusan S; de Fontbrune FS; Fuseau P; Najman A; Vainchenker W; Delhommeau F; Micol JB; Plo I; Bellanné-Chantelot C
Leukemia; 2022 Jan; 36(1):126-137. PubMed ID: 34172895
[TBL] [Abstract][Full Text] [Related]
12. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.
Beer PA; Delhommeau F; LeCouédic JP; Dawson MA; Chen E; Bareford D; Kusec R; McMullin MF; Harrison CN; Vannucchi AM; Vainchenker W; Green AR
Blood; 2010 Apr; 115(14):2891-900. PubMed ID: 20008300
[TBL] [Abstract][Full Text] [Related]
13. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
14. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
Thoennissen NH; Krug UO; Lee DH; Kawamata N; Iwanski GB; Lasho T; Weiss T; Nowak D; Koren-Michowitz M; Kato M; Sanada M; Shih LY; Nagler A; Raynaud SD; Müller-Tidow C; Mesa R; Haferlach T; Gilliland DG; Tefferi A; Ogawa S; Koeffler HP
Blood; 2010 Apr; 115(14):2882-90. PubMed ID: 20068225
[TBL] [Abstract][Full Text] [Related]
16. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Mascarenhas J; Heaney ML; Najfeld V; Hexner E; Abdel-Wahab O; Rampal R; Ravandi F; Petersen B; Roboz G; Feldman E; Podoltsev N; Douer D; Levine R; Tallman M; Hoffman R;
Leuk Res; 2012 Dec; 36(12):1500-4. PubMed ID: 22938832
[TBL] [Abstract][Full Text] [Related]
17. Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression.
Bartels S; Vogtmann J; Schipper E; Büsche G; Schlue J; Lehmann U; Kreipe H
Eur J Haematol; 2021 Apr; 106(4):520-528. PubMed ID: 33460496
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations in blast phase of BCR::ABL1-negative myeloproliferative neoplasms.
Chen D; Weinberg OK
Int J Lab Hematol; 2023 Dec; 45(6):839-844. PubMed ID: 37867386
[TBL] [Abstract][Full Text] [Related]
19. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm.
Fleischman AG
Mediators Inflamm; 2015; 2015():606819. PubMed ID: 26538830
[TBL] [Abstract][Full Text] [Related]
20. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
Abruzzese E; Niscola P
Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
